Liquid Biopsy MarketThe global liquid biopsy market is poised for substantial expansion, with an estimated revenue of USD 1,538.3 million in 2023. The market is projected to grow at an impressive ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Liquid biopsy is emerging as a less invasive method for cancer detection and monitoring. High adoption rates are seen in oncology and prenatal diagnostics. Liquid Biopsy Tube Market growth was valued ...

Exosomes, cell-free DNA (cfDNA), circulating tumor cells (CTC), and tumor microenvironment components, as critical components in PMN establishment, could be monitored by liquid biopsy. Intensive ...

Datar Cancer Genetics (DCG), a global leader in non-invasive cancer diagnostics, announces Dr. Massimo Cristofanilli as ...

As serum biomarkers are not optimal for early diagnosis, liquid biopsy has emerged as a promising tool for diagnosis, prognostication, and patients’ stratification for personalized therapy in various ...

In a statement, the UK medical device firm said its "liquid biopsy" approach "offers the prospect of a new era of personalised cancer care" and moves it closer to positioning Parsortix as a go-to ...

A new blood test has potential to identify a hard-to-predict but sometimes deadly pregnancy complication weeks before it ...

A new blood test has an 80% accuracy in predicting preterm preeclampsia, according to a study published today, Feb. 12, in ...

Emerging biomarkers like ctDNA and PTEN loss offer predictive and prognostic insights, enhancing personalized treatment strategies. Liquid biopsies, particularly ctDNA, are poised to transform disease ...